Finally, the fifth approach resulted in a good risk stratification and identification of luminal breast tumour patients with prognosis similar to those with triple-negative breast tumours for both DMFS (Ki-67>12% cHR≤4+ versus triple-negative, adjusted HaR: 0.691 (0.406–1.174), p = 0.172) and OS (Ki-67>12% cHR≤4+ versus triple-negative, adjusted HaR: 0.695 (0.416–1.161), p = 0.165). The gene discussed is MKI67; the disease is breast neoplasm.